Canadians facing persistent shortages of weight loss medications should take note that Wegovy, a medication approved for on-label use, is finally accessible in Canada. Developed by the same manufacturers as Ozempic, Novo Nordisk, Wegovy has officially become available as of Monday, despite receiving approval in Canada back in 2021. The arrival of Wegovy brings hope to individuals struggling with obesity and diabetes.
Novo Nordisk’s weekly injection, Wegovy, is authorized in Canada for weight loss in individuals diagnosed with obesity. Additionally, it can be prescribed to patients who are substantially overweight and have at least one associated medical condition, such as hypertension, Type 2 diabetes, or obstructive sleep apnea.
Wegovy is indeed effective, as during a 68-week medical trial involving 1,961 adults who were either obese or overweight with a related medical condition, participants experienced a weight loss of approximately 35 pounds, equivalent to around 15% of their initial body weight. In comparison, individuals who were administered a placebo, meaning they did not receive medication, experienced an average weight loss of about 6 pounds, representing approximately 2.5% of their starting body weight. The average initial weight for both groups was approximately 232 pounds.
However, with the excitement surrounding its release, inquiries about how Wegovy differs from medications like Ozempic, who are the ideal candidates for its use, and its potential side effects are likely to emerge.
Wegovy and Ozempic are both medications developed by Novo Nordisk, and they contain the same active ingredient, semaglutide. However, they are used for different purposes and administered at different doses.
- Indications:
- Wegovy (semaglutide 2.4 mg) is specifically approved for weight management in adults who are obese or overweight and have weight-related medical problems.
- Ozempic (semaglutide 0.5 mg or 1 mg) is primarily used for the treatment of type 2 diabetes in adults, although it has also shown benefits in reducing body weight in people with obesity or overweight.
- Dosage:
- Wegovy is available as a once-weekly injection containing a higher dose of semaglutide (2.4 mg).
- Ozempic is available as a once-weekly injection with lower doses of semaglutide (0.5 mg or 1 mg) for diabetes treatment.
- Treatment Focus:
- Wegovy is specifically designed to help with weight loss and is approved for use in individuals with obesity or overweight.
- Ozempic primarily targets blood sugar control in people with type 2 diabetes, although it may also contribute to weight loss as a secondary effect.
While Wegovy can be an effective tool for weight management, like any medication, it carries potential risks and side effects. Some of the dangers associated with Wegovy include:
- Gastrointestinal Side Effects: Common side effects of Wegovy include nausea, vomiting, diarrhea, constipation, and abdominal pain. These symptoms typically occur during the initial weeks of treatment and may decrease over time.
- Pancreatitis: There have been reports of pancreatitis (inflammation of the pancreas) in patients taking GLP-1 receptor agonists like Wegovy. Symptoms of pancreatitis include severe abdominal pain, nausea, vomiting, and fever. If left untreated, pancreatitis can be serious and even life-threatening.
- Gallbladder Problems: Some individuals may experience gallbladder-related complications such as gallstones or inflammation of the gallbladder (cholecystitis) while taking Wegovy. Symptoms may include abdominal pain, nausea, vomiting, and fever.
- Hypoglycemia: Although Wegovy is not intended for the treatment of diabetes, it may lower blood sugar levels. This can potentially lead to hypoglycemia (low blood sugar), especially when used in combination with other medications that lower blood sugar levels.
- Thyroid Tumors: In rodent studies, semaglutide has been associated with an increased risk of thyroid C-cell tumors. However, the relevance of these findings to humans is not fully understood, and the risk in humans remains uncertain.
- Heart Rate Increase: Semaglutide may cause an increase in heart rate, particularly at higher doses. This effect should be monitored, especially in individuals with pre-existing cardiovascular conditions.
It’s essential for Canadians considering Wegovy to discuss the potential risks and benefits with their healthcare provider. They should also undergo regular monitoring while taking the medication to detect any adverse effects early on.
Last but not least, the price of Wegovy in Canada may not be attractive for everyone, as it is expected to cost around $400 Canadian dollars a month.